CB
57
2
DNB
74
-6
DD
53
-6
DFS
64
2
EXC
54
3
VMC
53
-4
JNJ
41
3
NOV
52
-5
BBY
52
6
RHI
57
-6
AMZN
61
-5
ABT
59
2
SPG
60
2
CAH
48
-6
SRE
63
2
WYNN
36
-5
THC
60
-5
MAR
63
-5
GD
41
-4
CTAS
53
-3
CB
57
2
DNB
74
-6
DD
53
-6
DFS
64
2
EXC
54
3
VMC
53
-4
JNJ
41
3
NOV
52
-5
BBY
52
6
RHI
57
-6
AMZN
61
-5
ABT
59
2
SPG
60
2
CAH
48
-6
SRE
63
2
WYNN
36
-5
THC
60
-5
MAR
63
-5
GD
41
-4
CTAS
53
-3
Financhill
Back

Cellectis SA 10K Form

Sell
46

CLLS
Cellectis SA

Last Price:
1.86
Seasonality Move:
2.21%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLLS News And Ratings

See the #1 stock for the next 7 days that we like better than CLLS

CLLS Financial Statistics

Sales & Book Value

Annual Sales: $755K
Cash Flow: $-6.63M
Price / Cash Flow: 2.78
Annual Sales: $1.29
Price / Book: 1.45

Profitability

EPS (TTM): -1.34000
Net Income (TTM): $-84.48M
Gross Margin: $18K
Return on Equity: -79.78%
Return on Assets: -24.83%

Cellectis SA Earnings Forecast

Key Cellectis SA Financial Ratios

  • The Gross Profit Margin over the past 17 years for CLLS is 2.38%.
  • The Selling, General & Administrative Expenses for CLLS have been equal to 2,226.75% of Gross Profit Margin.
  • The Research & Development expenses have been 11,608.74% of Revenue.
  • The Interest Expense is -5.25% of Operating Income.
  • The Net Earning history of CLLS is -13,385.30% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Cellectis SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLLS
CUSIP: 15117K
Website: cellectis.com

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 1.78
Quick Ratio: 1.74

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLLS Technical Analysis vs Fundamental Analysis

Sell
46
Cellectis SA (CLLS) is a Sell

Is Cellectis SA a Buy or a Sell?

  • Cellectis SA stock is rated a Sell
    The current Cellectis SA [CLLS] share price is $1.87. The Score for CLLS is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.